跳至主要内容
临床试验/NL-OMON52290
NL-OMON52290招募中不适用

Minimal residual disease in peripheral blood compared to bone marrow in patients treated for acute myeloid leukemia - MRD in peripheral blood compared to bone marrow in AML patients

Vrije Universiteit Medisch Centrum0 个研究点目标入组 151 人开始时间: 待定最近更新:
适应症

试验速览

阶段
不适用
状态
招募中
入组人数
151

研究概览

简要总结

暂无简介。

研究设计

研究类型
Observational

入排标准

年龄范围
18 至 64(—)

入选标准

  • - Patient with:
  • o a diagnosis of AML and related precursor neoplasms according to WHO 2008
  • classification (excluding acute promyelocytic leukemia) including secondary AML
  • (after an antecedent hematological disease (e.g. MDS) and therapy-related AML),
  • o acute leukemia*s of ambiguous lineage according to WHO 2008 or
  • o a diagnosis of refractory anemia with excess of blasts (MDS) and IPSS-R score
  • - Treated according to HOVON clinical trials
  • - Age 18 yr or older
  • - A bone marrow aspiration has been scheduled
  • - WHO performance status 0, 1 or 2
  • - Written informed consent

排除标准

  • - Acute promyelocytic leukemia
  • - Pregnant or lactating females
  • - Unwilling or not capable to use effective means of birth control

研究者

相似试验